Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 90 of 5804
-
Experimental drug aims to reverse liver scarring in NASH cirrhosis
Disease control CompletedThis is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
Phase: PHASE2 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Brain pacemaker shows promise for severe OCD
Disease control CompletedThe present study aims to explore the efficacy and safety of DBS targeted the combination of the anterior limb of internal capsule and nucleus accumbens (ALIC/NAcc-DBS) to refractory OCD, based on multicenter, randomized, double-blinded, sham-stimulation controlled design, that c…
Phase: NA • Sponsor: Shanghai Mental Health Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: targeted drug combo faces off against standard care
Disease control OngoingThis study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with relapsed/refractory multiple myeloma.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to fight cervical cancer without chemo
Disease control OngoingThis study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enr…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:19 UTC
-
New combo therapy aims to wipe out rectal cancer before surgery
Disease control OngoingThe study is a multicenter, open-label, randomized controlled clinical study, and the purpose of the study is to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with short-term radiotherapy, sequential Camrelizumab and…
Phase: PHASE3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cocktail of drugs aims to tackle tough lung cancer
Disease control CompletedThe purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage s…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Brain artery stent coated with drug may cut stroke risk better than pills alone
Disease control Recruiting nowThe aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disea…
Phase: NA • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Groundbreaking trial aims to treat rare diseases in the womb
Disease control Recruiting nowFor detailed information, please view our study website: https://pearltrial.ucsf.edu/ The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New vaccine aims to stop dangerous e. coli infections in seniors
Prevention CompletedThe purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serot…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Gene therapy injection aims to halt fatal brain disease in babies
Disease control OngoingJ3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first…
Phase: PHASE1, PHASE2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug cocktail shows promise against deadly thyroid cancer before surgery
Disease control OngoingThis phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is a specific mutation (change) in the BRAF gene, which makes a protein that is involved in sendin…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New targeted combo aims to outsmart Hard-to-Treat colorectal cancer
Disease control OngoingStudy CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Phase: PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is a…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for advanced breast cancer: drug shows promise against brain tumors
Disease control OngoingThis is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed o…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could an amino acid shorten sickle cell pain crises?
Symptom relief CompletedThe trial is designed to test intravenous (IV) arginine therapy in children with sickle cell disease (SCD) and vaso-occlusive painful episodes (VOE) to further knowledge on efficacy and safety of this orphan drug.
Phase: PHASE3 • Sponsor: Claudia R. Morris • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Stem cells may help babies with spina bifida walk better
Disease control Recruiting nowSpina bifida, or myelomeningocele (MMC), is a birth defect that results in paralysis, excess fluid on the brain (hydrocephalus), and impaired ability to urinate and have bowel movements normally. In a previous study (the MOMS trial), surgery before birth (in-utero/fetal surgery) …
Phase: PHASE1, PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Weight-Loss drug semaglutide shows promise for heart failure with diabetes
Disease control CompletedThis study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart …
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Radioactive bullet targets tough prostate cancer in major trial
Disease control OngoingThe purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) particip…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Promising Gene-Targeting drug for ALS enters final trial phase
Disease control OngoingThe primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Promising new combo therapy for advanced prostate cancer enters final testing phase
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a c…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC